#USA #Azitra #Branford, Connecticut #ATR-COSF #rHDfilaggrin

Azitra, Inc. Introduces Groundbreaking Results in Dermatological Advancements

Azitra, Inc. has recently made significant strides in the field of dermatology with its ATR-COSF program, a clinical initiative focused on developing advanced treatments utilizing filaggrin, a vital protein for skin health. The company has announced encouraging outcomes from their latest ex vivo studies, showcasing remarkable results in terms of skin elasticity and anti-wrinkle properties when using their unique recombinant human domain of filaggrin (rHDfilaggrin).

ATR-COSF leverages a supernatant-based formulation derived from the bacterial strain Staphylococcus epidermidis, specially engineered to deliver rHDfilaggrin effectively. This innovative approach marks a pivotal moment in cosmetic dermatology, as it aims to enhance the skin's health while addressing common signs of aging such as fine lines and wrinkles.

In the first of two studies conducted, researchers were able to demonstrate the improved distribution of rHDfilaggrin compared to previous single-dose methodologies. The data revealed that the filtration enabled greater penetration into the stratum granulosum, highlighting the repeated application's efficiency. The use of fresh human skin explants allowed for an accurate biological assessment of the formulations, maintaining the structure reminiscent of actual human skin.

The initial results indicate that a single application of the new formulation led to significant penetrative capabilities, revealing that additional repeated doses could yield progressively better outcomes. Importantly, safety tests confirmed that the applied formulations posed no irritation risks to human skin, reinforcing their potential suitability for broader cosmetic use.

Moreover, Azitra conducted a secondary study on defatted human skin samples to assess the impact of varying concentrations of lyophilized rHDfilaggrin within hydrogel formulations. Findings indicated that the elasticity of the skin improved significantly, demonstrating a dose-dependent reaction. Lower concentrations of the active ingredient showed moderate improvements, while higher concentrations resulted in exceptional elasticity enhancement, restoring skin to levels typically associated with robust, youthful skin health.

The efficacy of the hydrogel formulation to enhance elasticity was particularly notable when comparing treated samples against controls. The results indicated that certain formulations could double the elasticity of skin, demonstrating the potential of this technology as a vital component in future anti-aging products.

Francisco Salva, the CEO of Azitra, conveyed his excitement about the findings, emphasizing the importance of continuing to refine formulations. This program is poised not only to elevate the standards of anti-wrinkle treatments but also to bring innovative skin health solutions to consumers globally.

As Azitra moves forward, the team is committed to expanding their research and transitioning towards human clinical trials with the aim of translating their groundbreaking science into tangible benefits for consumers. The ultimate goal remains clear: the development of effective treatments that can visibly reduce signs of aging, thereby enhancing the quality of life for countless individuals.

Azitra, Inc., founded with a mission to innovate in critical dermatological applications, is paving the way for the next generation of cosmeceuticals. Their ATR-COSF program, alongside their other therapeutic ventures, signifies their dedication to addressing pivotal skin health challenges, making strides in improving the well-being of individuals through scientifically-backed solutions.

For more information regarding Azitra, Inc. and their innovative offerings, visit their official website and explore the future of precision dermatology and skincare.